"When President Trump told an audience in October that he hoped to cut the cost of Ozempic down from around $1,000 to $150, Dr. Mehmet Oz quickly stepped in to backtrack. Oz, head of Medicare and Medicaid services, grabbed the mic and said it wasn't a done deal. But Trump had a believer in Mark Cuban - billionaire businessman, former Shark Tank "shark," and longtime critic of the president."
"Speaking to Business Insider on Wednesday, Cuban said he believed it was totally possible for Trump to seal a deal with Novo Nordisk and Eli Lilly, makers of the biggest GLP-1 drugs on the market. Trump seemed to prove him right Thursday, announcing $250 a month Wegovy, and $249 prices for anyone on Medicare using a GLP-1, plus the option for states to have $50 co-pays for Medicaid patients, starting in 2026."
"Cuban has been on his own yearslong crusade to reduce the cost of pharmaceutical drugs, via his pharmacy Cost Plus Drugs. His goal is to provide drugs at 'net price' - that is, the actual sticker price of the drug, instead of a higher 'list price' that's been negotiated between drugmakers and middlemen. 'Anything that impacts the middleman, I'm a fan of,' Cuban said of Trump's deal."
President Trump announced deals with Novo Nordisk and Eli Lilly to reduce prices for GLP-1 drugs, with one-month supplies starting between $150 and $250. The announcement listed $250 monthly Wegovy and $249 pricing for Medicare beneficiaries using a GLP-1, and offered states the option of $50 co-pays for Medicaid patients beginning in 2026. Mark Cuban said the deals were achievable and praised moves that limit middlemen. Cuban operates Cost Plus Drugs to sell medications at net price rather than higher negotiated list prices and recently arranged reduced pricing for an expensive Crohn's disease medication.
Read at Business Insider
Unable to calculate read time
Collection
[
|
...
]